Leflunomide Tablet, Film Coated
Product Images NDC 70710-1158

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 70710-1158). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals (usa) Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 01)

Chemical structure diagram of leflunomide, showing its molecular components including an oxazole ring attached to a benzene ring with trifluoromethyl substitution.*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 02)

Chemical structure diagram of teriflunomide, the active form of leflunomide. The structure shows a trifluoromethyl-substituted aromatic ring linked to an amide group and a conjugated cyano and hydroxyl-substituted methyl group, labeled A77 1726 (teriflunomide).*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 03)

A bar graph titled '% ACR 20 Responder at Endpoint' comparing response rates in three clinical trials over different durations (6 and 12 months). The graph shows percentage responders for leflunomide, methotrexate, placebo, and sulfasalazine, illustrating response rates at trial endpoints.*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 04)

A line graph titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders on the vertical axis and months on the horizontal axis. It compares response rates over 12 months for three groups labeled PL, MTX, and LEF, indicated by circles, squares, and triangles respectively. LEF shows the highest responder percentages throughout the period.*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 05)

A bar chart titled 'Change in Sharp Score' comparing disease progression across three clinical trials over 6 to 12 months. The chart shows progression values for leflunomide, methotrexate, sulfasalazine, and placebo groups, illustrating differences in Sharp Score changes between treatments in each trial.*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 06)

Bar graph titled 'Change in Functional Ability Measure' showing comparative results across three trials of 6 to 12 months. The graph measures improvement on the vertical axis from -0.6 to 0.2, with bars representing Leflunomide (L), Methotrexate (M), Placebo (P), and Sulfasalazine (S) treatments according to the HAQ Disability Index. Negative values indicate reduction in disability.*

FDA Label Image

Label (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 07)

Leflunomide Tablets, USP 10 mg film-coated tablet label displaying the product name, dosage strength, and package size of 30 tablets. The label includes manufacturer Zydus Lifesciences Ltd. and distributor Zydus Pharmaceuticals (USA) Inc. information, storage and handling instructions, and cautions. The NDC number 70710-1157-3 is also visible.*

FDA Label Image

Label (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 08)

Leflunomide 20 mg film-coated tablets packaging label showing the product name, strength, dosage form, and quantity of 30 tablets. Label displays the NDC 70710-1158-3 and manufacturer information: Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc. Usual dosage instructions and storage conditions are included with warnings about child resistance and drug safety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.